These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 22733026)

  • 1. Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myelodysplastic/myeloproliferative disorders: an analysis of 636 cases.
    Schnittger S; Bacher U; Alpermann T; Reiter A; Ulke M; Dicker F; Eder C; Kohlmann A; Grossmann V; Kowarsch A; Kern W; Haferlach C; Haferlach T
    Haematologica; 2012 Dec; 97(12):1890-4. PubMed ID: 22733026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.
    Tefferi A
    Leukemia; 2010 Jun; 24(6):1128-38. PubMed ID: 20428194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TET2, ASXL1, IDH1, IDH2, and c-CBL genes in JAK2- and MPL-negative myeloproliferative neoplasms.
    Martínez-Avilés L; Besses C; Álvarez-Larrán A; Torres E; Serrano S; Bellosillo B
    Ann Hematol; 2012 Apr; 91(4):533-41. PubMed ID: 21904853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular analyses of 15,542 patients with suspected BCR-ABL1-negative myeloproliferative disorders allow to develop a stepwise diagnostic workflow.
    Schnittger S; Bacher U; Eder C; Dicker F; Alpermann T; Grossmann V; Kohlmann A; Kern W; Haferlach C; Haferlach T
    Haematologica; 2012 Oct; 97(10):1582-5. PubMed ID: 22511494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CBL mutations in myeloproliferative neoplasms are also found in the gene's proline-rich domain and in patients with the V617FJAK2.
    Aranaz P; Hurtado C; Erquiaga I; Miguéliz I; Ormazábal C; Cristobal I; García-Delgado M; Novo FJ; Vizmanos JL
    Haematologica; 2012 Aug; 97(8):1234-41. PubMed ID: 22315494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms.
    Olcaydu D; Rumi E; Harutyunyan A; Passamonti F; Pietra D; Pascutto C; Berg T; Jäger R; Hammond E; Cazzola M; Kralovics R
    Haematologica; 2011 Mar; 96(3):367-74. PubMed ID: 21173100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms.
    Grand FH; Hidalgo-Curtis CE; Ernst T; Zoi K; Zoi C; McGuire C; Kreil S; Jones A; Score J; Metzgeroth G; Oscier D; Hall A; Brandts C; Serve H; Reiter A; Chase AJ; Cross NC
    Blood; 2009 Jun; 113(24):6182-92. PubMed ID: 19387008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activating CBL mutations are associated with a distinct MDS/MPN phenotype.
    Schwaab J; Ernst T; Erben P; Rinke J; Schnittger S; Ströbel P; Metzgeroth G; Mossner M; Haferlach T; Cross NC; Hochhaus A; Hofmann WK; Reiter A
    Ann Hematol; 2012 Nov; 91(11):1713-20. PubMed ID: 23010802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutational status of myeloproliferative neoplasms.
    Rumi E; Elena C; Passamonti F
    Crit Rev Eukaryot Gene Expr; 2010; 20(1):61-76. PubMed ID: 20528738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular aspects of myeloproliferative neoplasms.
    Delhommeau F; Jeziorowska D; Marzac C; Casadevall N
    Int J Hematol; 2010 Mar; 91(2):165-73. PubMed ID: 20186505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
    Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
    Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies.
    Makishima H; Cazzolli H; Szpurka H; Dunbar A; Tiu R; Huh J; Muramatsu H; O'Keefe C; Hsi E; Paquette RL; Kojima S; List AF; Sekeres MA; McDevitt MA; Maciejewski JP
    J Clin Oncol; 2009 Dec; 27(36):6109-16. PubMed ID: 19901108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes.
    Stein BL; Williams DM; O'Keefe C; Rogers O; Ingersoll RG; Spivak JL; Verma A; Maciejewski JP; McDevitt MA; Moliterno AR
    Haematologica; 2011 Oct; 96(10):1462-9. PubMed ID: 21712540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
    Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
    Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
    Iványi JL; Marton E; Plander M
    Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methylation of TET2, CBL and CEBPA in Ph-negative myeloproliferative neoplasms.
    Chim CS; Wan TS; Fung TK; Wong KF
    J Clin Pathol; 2010 Oct; 63(10):942-6. PubMed ID: 20671051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
    Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
    Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1.
    Kohlmann A; Grossmann V; Klein HU; Schindela S; Weiss T; Kazak B; Dicker F; Schnittger S; Dugas M; Kern W; Haferlach C; Haferlach T
    J Clin Oncol; 2010 Aug; 28(24):3858-65. PubMed ID: 20644105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations.
    Meggendorfer M; Bacher U; Alpermann T; Haferlach C; Kern W; Gambacorti-Passerini C; Haferlach T; Schnittger S
    Leukemia; 2013 Sep; 27(9):1852-60. PubMed ID: 23628959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of JAK2V617F mutation in Jordanian patients with myeloproliferative neoplasms.
    Jaradat SA; Khasawneh R; Kamal N; Matalka I; Al-Bishtawi M; Al-Sweedan S; Ayesh MH
    Hematol Oncol Stem Cell Ther; 2015 Dec; 8(4):160-6. PubMed ID: 26256826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.